REGN
REGN clinical trials: REGENERON PHARMACEUTICALS, INC.
Every trial on ClinicalTrials.gov where REGENERON PHARMACEUTICALS, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 807
- Trials linked
- 412
- As lead sponsor
- 395
- As collaborator
- 7
- Primary completions as lead sponsor, next 90 days
REGN on the catalyst calendar · REGN registry changes
- Primary completion May 17, 2027Sponsor estimatePhase 3NCT07213778REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult ParticipantsRegeneron Pharmaceuticals · Symptomatic Venous Thromboembolism (VTE)RecruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 5, 2031Sponsor estimatePhase 1NCT07753148Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk...Regeneron Pharmaceuticals · Clonal Cytopenia of Undetermined Significance (CCUS)RecruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 21, 2028Sponsor estimatePhase 2NCT07685808Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without DiabetesRegeneron Pharmaceuticals · Overweight or ObesityRecruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 11, 2029Sponsor estimatePhase 3NCT07626411Stroke and Systemic Embolism Prevention in Adult Participants With Atrial FibrillationRegeneron Pharmaceuticals · Atrial Fibrillation (AF)RecruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 15, 2030Sponsor estimatePhase 2NCT07527910A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLDRegeneron Pharmaceuticals · Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)RecruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 18, 2029Sponsor estimatePhase 3NCT07318610Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery DiseaseRegeneron Pharmaceuticals · Peripheral Artery Disease (PAD)RecruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 21, 2029Sponsor estimatePhase 3NCT07222761A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination...Regeneron Pharmaceuticals · Relapsed and/or Refractory Multiple Myeloma (RRMM)RecruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 14, 2034Sponsor estimatePhase 1/Phase 2NCT06379789A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric...Regeneron Pharmaceuticals · Hemophilia BRecruitingREGNLeadNTLACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 20, 2028Sponsor estimatePhase 1/Phase 2NCT06292780A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)Regeneron Pharmaceuticals · Relapsed/Refractory Systemic Light Chain AmyloidosisRecruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 3, 2029Sponsor estimatePhase 3NCT07854782Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Regeneron Pharmaceuticals · Metabolic Dysfunction-Associated Steatotic Liver DiseaseRecruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 29, 2023ActualPhase 1NCT05481333A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in the Body of Healthy ParticipantsRegeneron Pharmaceuticals · HealthyCompletedREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 17, 2024ActualPhase 1NCT04409080REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive TherapyRegeneron Pharmaceuticals · Severe Aplastic Anemia (SAA)TerminatedREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2, 2024ActualPhase 1NCT03005782Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced CancersRegeneron Pharmaceuticals · MalignanciesCompletedREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 10, 2031Sponsor estimatePhase 1/Phase 2NCT07863024Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets...Regeneron Pharmaceuticals · Advanced Solid TumorsRecruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 29, 2028Sponsor estimatePhase 3NCT06230224A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated...Regeneron Pharmaceuticals · B-Cell Non-Hodgkin Lymphoma (B-NHL)Active, not recruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 28, 2029Sponsor estimatePhase 3NCT07430956Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is UnsuitableRegeneron Pharmaceuticals · Atrial Fibrillation (AF)RecruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 29, 2029Sponsor estimatePhase 3NCT06097364A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab...Regeneron Pharmaceuticals · Follicular Lymphoma (FL)Active, not recruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 18, 2027Sponsor estimatePhase 3NCT07220772A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and AdultsRegeneron Pharmaceuticals · Monogenic ObesityRecruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 16, 2026ActualPhase 2NCT06299098A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult...Regeneron Pharmaceuticals · ObesityCompletedREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2031Sponsor estimatePhase 3NCT06149286A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in...Regeneron Pharmaceuticals · Relapsed/Refractory Follicular LymphomaRecruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 29, 2028Sponsor estimatePhase 3NCT06091254A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of...Regeneron Pharmaceuticals · Follicular Lymphoma (FL)RecruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 27, 2028Sponsor estimatePhase 2NCT05519475A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated...Regeneron Pharmaceuticals · Metabolic Dysfunction-Associated SteatoHepatitis (MASH)Active, not recruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 9, 2030Sponsor estimatePhase 2NCT06848088A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma TreatmentRegeneron Pharmaceuticals · MelanomaActive, not recruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 15, 2027Sponsor estimatePhase 3NCT05608291A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From...Regeneron Pharmaceuticals · MelanomaActive, not recruitingREGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 18, 2025ActualPhase 3NCT03088540Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)Regeneron Pharmaceuticals · Carcinoma,Non-Small-Cell LungCompletedREGNLeadSNYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 782 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner